STOCK TITAN

10x Genomics (NASDAQ: TXG) holder to sell about $871K in stock

(Neutral)
(Neutral)
Form Type
144

Rhea-AI Filing Summary

10x Genomics, Inc. (TXG) is the issuer of common stock covered by a notice of proposed sale filed for the account of Benjamin J. Hindson. The filing contemplates the sale of 13,373 shares of TXG common stock through Morgan Stanley Smith Barney LLC, with an aggregate market value of $870,849.76 and 120,212,296 shares of common stock outstanding. The shares relate to a Restricted Stock Unit Grant acquired on 08/21/2026, with services rendered as consideration.

Positive

  • None.

Negative

  • None.
Shares proposed to be sold 13,373 shares of common stock Number of shares to be sold under Rule 144
Aggregate market value $870,849.76 Aggregate market value of shares proposed to be sold
Shares outstanding 120,212,296 shares Shares of common stock outstanding as referenced in the notice
RSUs acquired 26,277 Amount of securities acquired via Restricted Stock Unit Grant
RSU acquisition date 08/21/2026 Date of acquisition of Restricted Stock Unit Grant
Approximate sale date 08/24/2026 Approximate date of the proposed sale under Rule 144
Rule 144 regulatory
"See the definition of "person" in paragraph (a) of Rule 144."
Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.
Restricted Stock Unit Grant financial
"Common Stock | 08/21/2026 | Restricted Stock Unit Grant | Issuer"
Services Rendered financial
"26277 | 08/24/2026 | Services Rendered"

FAQ

What does the Form 144 filing for TXG disclose about planned share sales?

The notice discloses a proposed sale of 13,373 shares of 10x Genomics, Inc. (TXG) common stock for the account of Benjamin J. Hindson. The sale is to be executed through Morgan Stanley Smith Barney LLC and is associated with previously granted equity compensation.

What is the aggregate market value of TXG shares covered by this Form 144?

The filing lists an aggregate market value of $870,849.76 for the 13,373 shares of 10x Genomics, Inc. common stock proposed to be sold under Rule 144.

How many TXG shares are outstanding as referenced in this Form 144?

The Form 144 references 120,212,296 shares of 10x Genomics, Inc. common stock as outstanding, providing context for the size of the proposed sale relative to total shares.

Who is the person for whose account TXG securities are to be sold?

The securities are to be sold for the account of Benjamin J. Hindson. The document is signed by Randy Wu acting as Attorney-in-Fact for Benjamin J. Hindson.

What is the origin of the TXG shares listed to be sold in this Form 144?

The shares are related to a Restricted Stock Unit Grant acquired on 08/21/2026 from the issuer, 10x Genomics, Inc., with services rendered identified as the nature of payment.

Through which broker will the proposed TXG share sale be executed?

The proposed sale of 10x Genomics, Inc. common stock is to be executed through Morgan Stanley Smith Barney LLC Executive Services, with the securities listed for trading on NASDAQ.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature